How Is Bioverativ’s Alprolix Positioned Now?
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.